Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kymera Therapeutics (KYMR) EPS (Basic): 2019-2025

Historic EPS (Basic) for Kymera Therapeutics (KYMR) over the last 6 years, with Sep 2025 value amounting to -$0.94.

  • Kymera Therapeutics' EPS (Basic) fell 14.63% to -$0.94 in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.60, marking a year-over-year decrease of 53.85%. This contributed to the annual value of -$2.98 for FY2024, which is 18.25% down from last year.
  • As of Q3 2025, Kymera Therapeutics' EPS (Basic) stood at -$0.94, which was up 1.05% from -$0.95 recorded in Q2 2025.
  • In the past 5 years, Kymera Therapeutics' EPS (Basic) registered a high of -$0.25 during Q4 2023, and its lowest value of -$0.95 during Q2 2025.
  • Moreover, its 3-year median value for EPS (Basic) was -$0.82 (2025), whereas its average is -$0.75.
  • Per our database at Business Quant, Kymera Therapeutics' EPS (Basic) skyrocketed by 97.17% in 2021 and then crashed by 256.00% in 2024.
  • Quarterly analysis of 5 years shows Kymera Therapeutics' EPS (Basic) stood at -$0.67 in 2021, then rose by 11.94% to -$0.59 in 2022, then surged by 57.63% to -$0.25 in 2023, then plummeted by 256.00% to -$0.89 in 2024, then dropped by 14.63% to -$0.94 in 2025.
  • Its EPS (Basic) was -$0.94 in Q3 2025, compared to -$0.95 in Q2 2025 and -$0.82 in Q1 2025.